Detalhe da pesquisa
1.
Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
Br J Cancer
; 127(3): 569-576, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35440668
2.
A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers.
Br J Cancer
; 125(10): 1333-1340, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34294893
3.
Volumetric imaging of the developing prepubertal mouse uterine epithelium using light sheet microscopy.
Mol Reprod Dev
; 85(5): 397-405, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29543367
4.
Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy.
Proc Natl Acad Sci U S A
; 110(52): 21030-5, 2013 Dec 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-24324164
5.
ß-Catenin is essential for Müllerian duct regression during male sexual differentiation.
Development
; 138(10): 1967-75, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21490063
6.
Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets.
JTO Clin Res Rep
; 5(2): 100623, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38357092
7.
Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.
Clin Cancer Res
; 29(16): 3237-3249, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37289191
8.
Chronic Estrus Disrupts Uterine Gland Development and Homeostasis.
Endocrinology
; 163(3)2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35134138
9.
Uterine gland formation in mice is a continuous process, requiring the ovary after puberty, but not after parturition.
Biol Reprod
; 85(5): 954-64, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21734259
10.
SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer.
Transl Lung Cancer Res
; 10(11): 4095-4105, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35004241
11.
A Reversible Shift of Driver Dependence from EGFR to Notch1 in Non-Small Cell Lung Cancer as a Cause of Resistance to Tyrosine Kinase Inhibitors.
Cancers (Basel)
; 13(9)2021 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33922104
12.
Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer.
Cancer Metab
; 9(1): 33, 2021 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34556188
13.
AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors.
Mol Cancer Res
; 19(3): 485-497, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33172976
14.
Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology.
J Thorac Oncol
; 16(11): 1821-1839, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34274504
15.
Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.
bioRxiv
; 2021 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32577652
16.
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
Cancer Cell
; 39(3): 346-360.e7, 2021 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33482121
17.
Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer.
J Clin Invest
; 131(1)2021 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33079728
18.
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer.
Nat Cancer
; 1: 423-436, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33521652
19.
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
J Thorac Oncol
; 15(5): 777-791, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068166
20.
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC.
J Thorac Oncol
; 14(12): 2152-2163, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31470128